Navigation Links
Sorbent Therapeutics Appoints Jason Levin Chief Business Officer

SUNNYVALE, Calif., Dec. 5, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that Jason Levin has joined the company as Chief Business Officer. 

Mr. Levin brings more than 18 years of industry experience to Sorbent. In this newly created role, he will oversee Sorbent's business development efforts and contribute to corporate strategy. Mr. Levin will report directly to Detlef Albrecht, M.D., Sorbent's President and CEO.

"Jason brings significant business development and corporate strategy expertise to our leadership team, and we have already benefitted from his business acumen in his role as an advisor to Sorbent for the past several months," said Dr. Albrecht. "Sorbent's lead product for heart failure, CLP1001, has achieved promising clinical results and our polymer technology platform allows us to create first-in-class therapeutics addressing significant unmet needs in heart failure, chronic kidney disease and hypertension.  Jason's contributions to building alliances and forming partnerships will accelerate the development and commercialization of our pipeline programs."

"With positive Phase 2a data for CLP1001, a solid management team and compelling partnering opportunities, this is an exciting time to join Sorbent.  CLP1001 has demonstrated measurable clinical improvements in the quality of life for heart failure patients by reducing fluid overload," said Jason Levin.  "Sorbent is well positioned for a variety of strategic collaborations as we commence our planned Phase 2b study for CLP1001, and evaluate opportunities to leverage the company's technology platform to generate non-absorbed polymer-based therapeutics that restore fluid and ion balances."

Jason Levin
Mr. Levin has been responsible for the completion of significant strategic transactions across several companies generating more than $500 million in value. Before joining Sorbent, Mr. Levin was responsible for in-licensing, out-licensing and partnering as Chief Business Officer at BrainCells Inc. a drug discovery and development company in San Diego, CA. Prior, he was Vice President Corporate Development at Jazz Pharmaceuticals, a specialty pharmaceutical company, where he was responsible for licensing, acquisitions, corporate strategy and strategic alliances.  Before joining Jazz Pharmaceuticals, Mr. Levin was director of business development at ALZA Corporation, a wholly owned subsidiary of Johnson & Johnson, where he was responsible for both in- and out-licensing of the company's drug delivery technology. Mr. Levin received an M.B.A. from the University of Texas, McCombs Graduate School of Business, and a Bachelor's Degree from the University of California at San Diego.  He has been a member of the Licensing Executive Society since 2000.

About Sorbent
Sorbent Therapeutics is a private biopharmaceutical company developing therapies for patients requiring targeted cation and fluid removal from the body.  The company is focused on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, end-stage renal disease, chronic kidney disease and hypertension.  Sorbent is headquartered in Sunnyvale, California.  For more information, visit

SOURCE Sorbent Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
2. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
3. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
4. Flexion Therapeutics Secures $20 Million in Series B Financing
5. Echo Therapeutics Announces Proposed Public Offering
6. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
7. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
8. Epizyme Publishes Current Review on Targeting Protein Methyltransferases for Personalized Cancer Therapeutics
9. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
10. Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
11. Echo Therapeutics Hires Daniel Sunday as Vice President of Manufacturing and Global Supply Chain
Post Your Comments:
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):